Trials / Completed
CompletedNCT06238817
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 241 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib Cream | Ruxolitinib cream applied topically to the affected area as a thin film twice daily. |
| DRUG | Vehicle Cream | Matching vehicle cream applied topically to the affected area as a thin film twice daily. |
Timeline
- Start date
- 2024-04-26
- Primary completion
- 2025-05-21
- Completion
- 2025-10-17
- First posted
- 2024-02-02
- Last updated
- 2025-10-28
Locations
94 sites across 14 countries: United States, Australia, Belgium, Bulgaria, Canada, France, Germany, Hungary, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06238817. Inclusion in this directory is not an endorsement.